Product Description

Recombinant Human VEGF165

Catalog Number: TL-612

Gene Name Synonym: MVCD1,VEGF,VEGF16,VPF

Construction: A DNA sequence encoding the human VEGF165 (NP_001165097.1) was expressed with a polyhistidine tag at the C-terminus.

Source: Human

Expression Host: HEK293 Cells

QC Testing Purity: > 95 % as determined by SDS-PAGE

Bio Activity: Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 ng/ml.

Endotoxin: ≤ 0.01 EU per μg of the protein as determined by the LAL method

Molecular Mass: The Recombinant Human VEGF165 consists of 193 amino acids and predicts a molecular mass of 22.3 KDa.

Formulation: Lyophilized from sterile PBS, pH 7.4. Normally 6 % - 8 % trehalose, mannitol are added as protectants before lyophilization.

Stability & Storage: Samples are stable for up to 24 months from date of receipt at 4 ℃. 

Recommend to aliquot the protein into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.

Protein Description

VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product.

References

1. Woolard J. et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64(21): 7822-7835.

2. Jia SF, et al. (2008) VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+)  cells. J Exp Ther Oncol. 7(2): 89-97.

3. Cimpean AM, et al. (2008) Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast  carcinoma. Rom J Morphol Embryol. 49(3): 303-8.

Trial dosage: A customer can apply for up to five samples a year (the actual trial dosage is determined by telephone or email communication).
Scope of use: Samples are limited to testing and research purposes.
Cost: Free for samples, customer is responsible for shipping and handling charges, reference cost is $50 in the US, €60 in the EU, and $50 in other countries.
How to apply: You can apply by telephone or by email (the email application should specify the sample name, item number, contact person, telephone number, consignee address, etc.).

Payment Terms︰ TT